Helsinn and Mundipharma China Pharmaceutical collectively announces the launching of the ALOXI IV in China along with a Co-Detailing teamwork in Shanghai

Helsinn and Mundipharma China Pharmaceutical together announce the launch of ALOXI® IV in China and a Co-Detailing collaboration in Shanghai

Lugano, Switzerland, and Beijing, China, May 9, 2019: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the Chinese market leader of pain management, today announced the availability of ALOXI® IV in China.

This is Helsinn’s first cancer supportive care product to be launched in the Chinese market, and for which Mundipharma China Pharmaceutical has exclusive marketing, promotion and sales rights. This product was approved by the National Medical Products Administration (NMPA) in November 2018.

The launch of ALOXI® IV in China, has also seen the initiation of a long co-detailing collaboration with Helsinn Pharmaceuticals (Beijing) Co., Ltd. in the municipality of Shanghai for ALOXI® IV and other future cancer care products in the Chinese market.
Andrea Meoli, Helsinn Group Chief Commercial Officer, commented: “ALOXI® IV is the first cancer supportive care product that we make available to Chinese patients. Since its launch in the other countries, ALOXI® has been effectively used for the prevention of CINV, helping to define the standard of care for the condition, and we are delighted that it is now becoming available to patients in China. We are pleased to be collaborating with Mundipharma China Pharmaceutical, a strategic partner, in introducing this product in China and co-detailing it in Shanghai and thereby helping patients in China to benefit from this treatment option.”

“The Launch of ALOXI® IV identifies expansion of strategic cooperation between Helsinn and Mundipharma China Pharmaceutical.” Said Peter Wang, General Manager, Mundipharma Pharmaceutical Greater China, “I believe there will be more CINV products with cutting-edge technologies to be brought into China market through the joint efforts of both sides, which will benefit more Chinese cancer patients.”

In the future, Mundipharma China will continue to explore in pain management field and expand its business into new fields, including CINV, transplantation immunology, oncology, respiratory, consumer health and etc. We’ll make unremitting efforts to providing innovative products and fulfilling our social responsibilities, ultimately to realize our vision of “Bring More to Life”.

, , , ,